Legislation & Regulation

In an op-ed for the Guardian, cardiologist Aseem Malhotra writes: “Corporate greed and systematic political failure have brought healthcare to its knees. There are too many misinformed doctors and misinformed patients. It’s time for greater transparency and stronger accountability, so that doctors and nurses can provide the best quality care for the most important person in the consultation room – the patient.”

The science magazine RUBIN provides an update on patients’ rights to refuse treatment in Germany's psychiatric wards. “In psychiatric wards in Germany, patients used to be medicated indiscriminately against their will if doctors considered it necessary. It was only after a Federal Constitution Court ruling a few years ago that patient autonomy has been strengthened.”

In a Science Update, the National Institute of Mental Health (NIMH) reports that Medicaid services is already taking steps to implement “coordinated specialty care” (CSC) in response to the RAISE study released last week. “The RAISE initiative has shown that coordinated specialty care for first episode psychosis is better than the standard care offered in community clinics. However, covering the cost of coordinated specialty care can be challenging. When Medicaid agrees to pay for effective treatment programs, patients in need benefit.”

The percentage of seniors in the United States prescribed potentially deadly antipsychotic drugs increases with age. A new study reveals that in the face of serious risks of strokes, fractures, kidney injuries, and death, over seventy-five percent of seniors given antipsychotics do not have a diagnosis for a mental disorder.

Former president of Psychologists for Social Responsibility (PsySR), Roy Eidelson discusses efforts to undermine the Hoffman report which revealed the American Psychologica Association’s collusion in torture. "First, from a familiar playbook, we have the obligatory attack on the patriotism of Hoffman and those who have criticized psychologists’ participation in abusive detention and interrogation operations,” he writes. “The most outrageous example comes from two retired military officers, David Bolgiano and John Taylor. In a recent piece they described the Hoffman Report as a ‘classic attack of cowards’ and also stated, ‘By the publication and release of this report, the APA becomes a willing co-conspirator to the likes of al Qaeda and ISIS.’”

At CounterPunch, Joseph Natoli connects Big Pharma, mass shootings, and rampant inequality. He writes: “The Brave New World soma strategy to deal with a population that, were they not doped up, might violently disrupt that brave new world, is useful if a society is ‘creatively destroying’ a growing number of its population each day. While the poor have daily evidence of their poverty, a collapsing middle class live in the illusion that they are middle class and just a short distance, not from ruin, but from fame and fortune. They are, in short, heading for a catastrophic break-down. Big Pharma is already set to give us all a ‘soft landing.’”

Despite safety concerns, a new study reveals that there has been no change in the use of benzodiazepines in the elderly from 2001 to 2010.

In a bellwether case, plaintiffs allege that Pfizer did not adequately warn patients that Zoloft (sertraline) would cause birth defects. The case is scheduled in Federal Court in March, and the verdict will have significant implications for future suits.

PsychCentral presents a new study from the Center for Disease Control and Prevention (CDC) that found that foster care children are three times more likely than other children on Medicaid to receive a diagnosis of ADHD. Overall, more than one in four children in foster care receive such a diagnosis. CDC statistician Melissa Danielson interpreted these results as revealing a “substantial need” for more medical and behavioral services for kids in foster care.

The UK Times reports that pharmaceutical companies are actively lobbying to limit the release of clinical trial data to the public. Rather than limiting results and data to medical journals, new transparency initiatives are pushing for making the information publically available. The push for transparency comes in the wake of the reanalysis of the Study 329 data on paroxetine (marketed as Seroxat and Paxil), which found that the industry study had misconstrued its results.

Results of a new study reveal that sixty-nine percent, or more than two-thirds, of patients prescribed antidepressant drugs have never, in their medical history, met the criteria for major depression. The study, published in the Journal of Clinical Psychiatry this month, also found that several demographic factors, like race and gender, were associated with the prescription of antidepressants.

Over at CounterPunch, Carl Boggs takes on the knee-jerk mental illness response that pervades the airwaves after every mass shooting. He writes: “What the mental-health fixation lacks is any semblance of historical or social context. Given the persistence of U.S. imperialism and militarism — and mounting fascination with combat and guns in a society transfigured by its warfare state — Washington remains a thriving center of global violence: repeated armed interventions abroad have found their domestic parallel in the world’s largest prison system, a deepening gun culture, home-bred terrorism, police atrocities, and a media culture filled with spectacles of warfare and bloodshed.”

A California jury ruled that Johnson & Johnson’s Janssen Pharmaceutical and a psychiatrist were responsible for the death of 25-year-old Leo Liu. During a clinical trial for Risperdal, Liu died of a heart injury that was “further complicated” by the drug and ignored by the study doctors. Janssen was found 70% responsible for Liu’s death and ordered to pay $5.6 million to the family.

“Genetic explanations for violent crimes may encourage jurors to support an insanity defense, but jurors may also believe the defendant is a persistent threat who will commit more crimes in the future,” Science Daily reports. A study on over 600 participants found that when people read a genetic explanation for a violent murder they attributed less blame to the defendant but recommended a longer sentence.

The Scientific American reports on a new analysis of antidepressant trials revealing that the vast majority of meta-analyses have industry links and suppress negative results.

On her blog, A Disordered World, psychiatric survivor Jeanene Harlick writes that “prejudicial rhetoric about the mentally ill, following mass shootings, is exacerbating the already-overwhelming stigma, discrimination and oppression we experience as an unrecognized and disadvantaged minority group.”

Yesterday, the New York Times reported that schizophrenia patients in an experimental treatment program (RAISE) who experienced better outcomes had been on lower doses of antipsychotics than normal. However, the article published in the American Journal of Psychiatry on Tuesday did not divulge any data on the varying antipsychotic drug doses in the different study groups.

Despite concerns about the drug’s necessity, effectiveness, and side-effects, Flibanserin (Addyi) has come to market as the first drug designed to increase sexual desire in women

Bernie Sanders joins numerous public health groups and opposes Robert Califf's nomination to lead the FDA over industry ties.

Johnson & Johnson is exposed to personal injury and product liability lawsuits over the failure to warn about Risperdal gynecomastia side effects in boys.

Writing for the Huffington Post, Caroline Beaton looks into how drugs continue to make billions in sales even after they lose lawsuits for fraud and misconduct. “The persistence of Big Pharma's fraud despite ubiquitous legal action suggests that our present efforts to hold the industry accountable are ineffective,” Beaton writes. “New polices in motion will make potentially unsafe drugs even easier to bring to market and promote.”

Matthew Cooper, writing for Newsweek, reports that despite the preponderance of political rhetoric about “mental illness” after mass shootings, a review of the research suggests that the connection between mental health and gun violence is dubious.

A former Navy pilot claims that a VA doctor misdiagnosed him with a mental disorder that prevented him from flying and ended his career. William Royster was told in 2004 that he was bipolar, that it was a permanent condition, and that he could no longer work in any capacity, according to the Navy Times. A different psychiatrist, however, later told Royster that he never met the criteria for diagnosis.

While a great deal of the excitement about advances in psychological treatments comes from the potential for research in neuroscience to unlock the secrets of the brain, many mental health experts would like to temper this enthusiasm. A special issue of the Behavior Therapist released this month calls into question the predominant conception of mental illnesses as brain disorders.

There is accumulating evidence that taking SSRI antidepressants increases the risk of bleeding and other complications during surgery, according to a review published in the British Journal of Anaesthesia.